S7 Table. Patient characteristics of the matched cohort (chemotherapy with TRT vs. chemotherapy with ICI)

Characteristic	Chemotherapy with TRT (n=32)	Chemotherapy with ICI (n=32)	p-value	SMD
Age group (yr)			0.58	0.15
< 65	8 (25.0)	10 (31.3)		
≥ 65	24 (75.0)	22 (68.8)		
Sex			> 0.99	0.01
Female	5 (15.6)	5 (15.6)		
Male	27 (84.4)	27 (84.4)		
ECOG performance status			0.49	0.08
0–1	29 (90.6)	31 (96.9)		
2	3 (9.4)	1 (3.1)		
Smoking status			0.32	0.03
Never smoked	7 (21.9)	4 (12.5)		
Current or former smoker	25 (78.1)	28 (87.5)		
No. of involved extrathoracic sites			0.39	0.19
0-1	25 (78.1)	22 (68.8)		
≥ 2	7 (21.9)	10 (31.3)		
Brain metastasis at diagnosis			0.77	0.07
No	25 (78.1)	24 (75.0)		
Yes	7 (21.9)	8 (25.0)		
Bone metastasis at diagnosis			0.42	0.19
No	23 (71.9)	20 (62.5)		
Yes	9 (28.1)	12 (37.5)		
Liver metastasis at diagnosis			0.45	0.14
No	29 (90.6)	27 (84.4)		
Yes	3 (9.4)	5 (15.6)		
Pleural metastasis at diagnosis			0.49	0.14
No	26 (81.3)	28 (87.5)		
Yes	6 (18.8)	4 (12.5)		
Follow-up duration (mo)			0.58	0.13
< 10	10 (31.3)	8 (25.0)		
≥ 10	22 (68.8)	24 (75.0)		
Response to 1st line systemic therapy[a]			0.55	0.09
SD or PD	2 (6.3)	1 (3.1)		
PR or CR	30 (93.8)	31 (96.9)		

CR, complete response; ECOG, Eastern Cooperative Oncology Group; ICI, immune check inhibitor; IQR, interquartile range; PD, progressive disease; PR, partial response; SD, stable disease; SMD, standardized mean difference. [a]Median number of 1st line systemic therapy cycles was 6 (IQR, 4 to 6) in the TRT alone group; 4 (IQR, 4 to 4) in the ICI group.